Buserelin as primary therapy in advanced prostatic carcinoma

Autor: Armand Bouzaglou, Peter S. Kennedy, Virginia L. Naessig, Melody R. Wyres, Daniel Eventov, Mark S. Soloway, Kimball S. Ford, John W. Kosola, Charles L. Wiseman, Sol S. Klioze, Alun L. Yakabow, Rafael G. Mendez, Barton Tanenbaum, Cary A. Presant
Rok vydání: 1985
Předmět:
Zdroj: Cancer. 56:2416-2419
ISSN: 1097-0142
0008-543X
DOI: 10.1002/1097-0142(19851115)56:10<2416::aid-cncr2820561013>3.0.co;2-#
Popis: The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38%), median duration greater than 5 months, and only two patients progressed. Performance status improved in 38%, patient-scored pain improved in 46%, and quality of life improved in 57%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25% increase in testosterone in 36% of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.
Databáze: OpenAIRE
Externí odkaz: